PMID- 15842048
OWN - NLM
STAT- MEDLINE
DCOM- 20050505
LR  - 20141120
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 123
IP  - 2
DP  - 2005 Feb
TI  - Chromogenic in situ hybridization for the detection of HER-2/neu gene 
      amplification in breast cancer with an emphasis on tumors with borderline and 
      low-level amplification: does it measure up to fluorescence in situ 
      hybridization?
PG  - 237-43
AB  - We compared chromogenic in situ hybridization (CISH) with fluorescence in situ 
      hybridization (FISH) for assessing HER-2/neu gene amplification using tissue 
      microarrays (TMAs) made from formalin-fixed, paraffin-embedded tissue blocks from 
      113 cases of invasive breast carcinoma. TMAs were created using 0.6-mm tissue 
      cores with 4 sampled cores per tumor. For both assays, a HER-2/chromosome 17 
      signal ratio of 2.0 or more was considered positive for gene amplification. The 
      average ratio of cores from the same tumor was used for determination of gene 
      amplification status of that particular tumor Of 113 cases, 102 were tested 
      successfully by both assays. The results were concordant in 100.0% of cases (63 
      amplified; 39 nonamplified). All 22 cases of borderline (ratio, 2.0-2.5) or 
      low-level (ratio, 2.6-3.9) amplification by FISH also showed HER-2 gene 
      amplification by CISH. CISH is as sensitive as FISH in detecting borderline and 
      low-level HER-2 amplification. Reliable recognition of the invasive carcinoma 
      area by light microscopy and preservation of the test slides are added advantages 
      of CISH. CISH performs as well as FISH in the analysis of HER-2 gene 
      amplification in breast cancer and might have advantages in certain situations.
FAU - Bhargava, Rohit
AU  - Bhargava R
AD  - Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 
      10021, USA.
FAU - Lal, Priti
AU  - Lal P
FAU - Chen, Beiyun
AU  - Chen B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Chromogenic Compounds)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*genetics/pathology
MH  - Carcinoma, Ductal, Breast/*genetics/pathology
MH  - Chromogenic Compounds
MH  - Female
MH  - *Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Receptor, ErbB-2/genetics/metabolism
MH  - Reproducibility of Results
MH  - Tissue Array Analysis
EDAT- 2005/04/22 09:00
MHDA- 2005/05/06 09:00
CRDT- 2005/04/22 09:00
PHST- 2005/04/22 09:00 [pubmed]
PHST- 2005/05/06 09:00 [medline]
PHST- 2005/04/22 09:00 [entrez]
PST - ppublish
SO  - Am J Clin Pathol. 2005 Feb;123(2):237-43.